Søren Bregenholt (CEO)
Søren Bregenholt - born 1971, Chief Executive Officer – holds a PhD in biomedical research from University of Copenhagen and did his post-doctoral training at Institute Pasteur in Paris. Søren has more than 20 years of international experience from operational and strategic leadership positions in global pharma and the biotech industry including executive roles at Novo Nordisk, Symphogen and Macrophage Pharma. He has negotiated and operationalized numerous licensing, collaboration and co-development agreements. Employed since June 2021 and member of the Management Team since 2021.
Other current positions: Chairman of Medicon Valley Alliance, Chairman of A Bioscience Incentive AB and Atlas Therapeutics AB.
Holdings in Alligator: 182,496 shares and 500,000 warrants in program TO 2022/2025 I.
Malin Carlsson (EVP & COO)
Malin Carlsson - born 1968, Executive Vice President & Chief Operating Officer – is a medical doctor with board certification in clinical immunology at Lund University. Malin has 20 years of research experience in immunology 12 years of experience in clinical drug development. Employed since 2020 and member of the Management Team since 2020.
Other current positions: None
Holdings in Alligator: 10,000 shares and 250,000 warrants in program TO 2022/2025 I.
Peter Ellmark (CSO)
Peter Ellmark – born 1973, Chief Scientific Officer – holds a PhD and an associate professorship in Immunotechnology at Lund University. Peter has more than 15 years’ experience of developing antibodies for immunotherapy of cancer. Employed since 2008 and member of the Management Team since 2018.
Other current positions: None
Holdings in Alligator: 40,000 shares and 250,000 warrants in program TO 2022/2025 I.
Marie Svensson (CFO)
Marie Svensson – born 1964, Chief Financial Officer since 2020 – has a Bachelor of Science in accounting and a Master of Business Administration/Management from Lund University. Marie has more than 20 years of experience from various financial positions in the high-tech industry. Employed since 2020 and member of the Management Team since 2020.
Other current positions: Board member of A Bioscience Incentive AB and Atlas Therapeutics AB.
Holdings in Alligator: 48,000 shares and 250,000 warrants in program TO 2022/2025 I.